BSX icon

Boston Scientific

98.66 USD
+0.49
0.50%
At close Jan 17, 4:00 PM EST
After hours
98.66
+0.00
0.00%
1 day
0.50%
5 days
5.16%
1 month
9.10%
3 months
14.16%
6 months
27.45%
Year to date
10.38%
1 year
61.84%
5 years
122.81%
10 years
588.49%
 

About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Employees: 48,000

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

114% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 76

18% more repeat investments, than reductions

Existing positions increased: 552 | Existing positions reduced: 467

6% more funds holding

Funds holding: 1,290 [Q2] → 1,364 (+74) [Q3]

6% more capital invested

Capital invested by funds: $106B [Q2] → $111B (+$5.83B) [Q3]

3% less funds holding in top 10

Funds holding in top 10: 36 [Q2] → 35 (-1) [Q3]

3.06% less ownership

Funds ownership: 93.25% [Q2] → 90.19% (-3.06%) [Q3]

31% less call options, than puts

Call options by funds: $674M | Put options by funds: $972M

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$98
1%
downside
Avg. target
$104
6%
upside
High target
$110
11%
upside

11 analyst ratings

11 positive
100%
neutral
0%
negative
0%
Truist Securities
Richard Newitter
79% 1-year accuracy
33 / 42 met price target
11%upside
$110
Buy
Maintained
18 Dec 2024
JP Morgan
Robbie Marcus
62% 1-year accuracy
13 / 21 met price target
11%upside
$110
Overweight
Maintained
16 Dec 2024
TD Cowen
Joshua Jennings
43% 1-year accuracy
9 / 21 met price target
11%upside
$110
Buy
Maintained
12 Dec 2024
Citigroup
Joanne Wuensch
60% 1-year accuracy
28 / 47 met price target
8%upside
$107
Buy
Maintained
11 Dec 2024
Wells Fargo
Larry Biegelsen
63% 1-year accuracy
29 / 46 met price target
1%upside
$100
Overweight
Maintained
11 Dec 2024

Financial journalist opinion

Based on 32 articles about BSX published over the past 30 days

Positive
Zacks Investment Research
7 hours ago
BSX Stock Rises on Positive Data Announcement at the AF Symposium
Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.
BSX Stock Rises on Positive Data Announcement at the AF Symposium
Neutral
Zacks Investment Research
2 days ago
Boston Scientific (BSX) Increases Yet Falls Behind Market: What Investors Need to Know
Boston Scientific (BSX) closed the most recent trading day at $98.66, moving +0.5% from the previous trading session.
Boston Scientific (BSX) Increases Yet Falls Behind Market: What Investors Need to Know
Neutral
PRNewsWire
3 days ago
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential procedures MARLBOROUGH, Mass. , Jan. 16, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device, respectively, during a late-breaking science session at AF Symposium 2025.
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
Neutral
Zacks Investment Research
5 days ago
PBH or BSX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
PBH or BSX: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
5 days ago
M&A Synergies Drive BSX: Is it Worth Buying the Stock Now?
Boston Scientific's recent acquisitions have added numerous products with immense potential.
M&A Synergies Drive BSX: Is it Worth Buying the Stock Now?
Positive
FXEmpire
5 days ago
Boston Scientific Jumps Ahead of Earnings
Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.
Boston Scientific Jumps Ahead of Earnings
Neutral
Zacks Investment Research
6 days ago
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Boston Scientific (BSX) settling at $94.61, representing a -0.28% change from its previous close.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Neutral
CNBC Television
1 week ago
Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
The Investment Committee discuss some stocks on the move today.
Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
Positive
Zacks Investment Research
1 week ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Positive
Zacks Investment Research
1 week ago
BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement
Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.
BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement
Charts implemented using Lightweight Charts™